GAITHERSBURG, Md.--(BUSINESS WIRE)--Dec. 21, 2006--Emergent
BioSolutions Inc. (NYSE: EBS) today announced that it will present at
the 25th Annual JPMorgan Healthcare Conference in San Francisco. Fuad
El-Hibri, president, chief executive officer and chairman of the board
of directors of Emergent BioSolutions will provide a company overview
and outline future growth opportunities at 3:00 pm PST, Monday,
January 08, 2007 at the St. Francis Hotel in San Francisco,
A webcast of the presentation will be available both live and by
replay. To access both the live and archived webcast, please go to
www.emergentbiosolutions.com, click on the "Investors" link and
proceed to the "Webcasts & Presentations" section. The archived replay
will be available 24 hours after the live presentation and will be
accessible for 30 days.
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc. is a biopharmaceutical company focused
on the development, manufacture and commercialization of
immunobiotics. Immunobiotics are vaccines and immune globulins that
induce or assist the body's immune system to prevent or treat disease.
The company's biodefense business is focused on developing and
commercializing immunobiotics for use against biological agents that
are potential weapons of bioterrorism. The company's commercial
business is focused on developing immunobiotics for use against
infectious diseases with significant unmet or underserved medical
needs. More information on the company is available at
CONTACT: Emergent BioSolutions Inc.
Robert G. Burrows, 301-795-1877
Vice President, Corporate Communications
SOURCE: Emergent BioSolutions Inc.